Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical considerations for the management of androgen indifferent prostate cancer
Jacob E. Berchuck, Paul V. Viscuse, Himisha Beltran, et al.
Prostate Cancer and Prostatic Diseases (2021) Vol. 24, Iss. 3, pp. 623-637
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Lina Merkens, Verena Sailer, Davor Lessel, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 88
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Silke Gillessen, Fabio Turco, Ian D. Davis, et al.
European Urology (2024)
Open Access | Times Cited: 20
Therapy considerations in neuroendocrine prostate cancer: what next?
Himisha Beltran, Francesca Demichelis
Endocrine Related Cancer (2021) Vol. 28, Iss. 8, pp. T67-T78
Open Access | Times Cited: 63
Targeting prostate cancer via therapeutic targeting of PIM-1 kinase by Naringenin and Quercetin
Aanchal Rathi, Arunabh Chaudhury, Farah Anjum, et al.
International Journal of Biological Macromolecules (2024) Vol. 276, pp. 133882-133882
Closed Access | Times Cited: 9
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis
Jacob E. Berchuck, Sylvan C. Baca, Heather M. McClure, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 5, pp. 928-938
Open Access | Times Cited: 48
Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker
Filip Ionescu, Jingsong Zhang, Liang Wang
Cancers (2022) Vol. 14, Iss. 7, pp. 1728-1728
Open Access | Times Cited: 26
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer
Landon C. Brown, Susan Halabi, Jason A. Somarelli, et al.
Prostate Cancer and Prostatic Diseases (2022) Vol. 25, Iss. 4, pp. 762-769
Open Access | Times Cited: 24
Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view
Fahimeh Lavi Arab, Akram Hoseinzadeh, Fatemeh Hafezi, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112171-112171
Closed Access | Times Cited: 5
Cancer Stem Cells and Prostate Cancer: A Narrative Review
Yazan Al Salhi, Manfredi Bruno Sequi, Fabio Maria Valenzi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7746-7746
Open Access | Times Cited: 13
Gold Nanoparticle Inhibits the Tumor‐Associated Macrophage M2 Polarization by Inhibiting m6A Methylation‐Dependent ATG5/Autophagy in Prostate Cancer
Yuanyuan Hao, Feng Duan, Xianning Dong, et al.
Analytical Cellular Pathology (2025) Vol. 2025, Iss. 1
Open Access
Exploring Therapeutic Strategies for Androgen-Independent Prostate Cancer Using a Magnetic Coculture Platform
Anjani Chavali, Giles Fitzwilliams, Adam Germain, et al.
Biomedical Engineering Advances (2025), pp. 100144-100144
Open Access
Clinical and Genomic Features of Androgen Indifferent Prostate Cancer
Jack Masur, Aakrosh Ratan, Krzysztof Wierbiłowicz, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 679-679
Open Access
Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future
Matthew Siskin, Minas P. Economides, David R. Wise
Cancers (2025) Vol. 17, Iss. 5, pp. 774-774
Open Access
Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications
Daniël J. Vis, Sander Palit, Marie Corradi, et al.
Genome Medicine (2025) Vol. 17, Iss. 1
Open Access
Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate cancer
Hengfeng Zhou, Qiangrong He, Chao Li, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 14
Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer
Naohiro Fujimoto, Yuto Tsubonuma, Yujiro Nagata, et al.
Anticancer Research (2023) Vol. 43, Iss. 9, pp. 3841-3847
Open Access | Times Cited: 8
Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy
Kim van der Zande, R.D. Tutuhatunewa-Louhanepessy, Paul Hamberg, et al.
Clinical Genitourinary Cancer (2024) Vol. 22, Iss. 2, pp. 445-453.e1
Open Access | Times Cited: 2
Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer
Irene Zamora, Michael R. Freeman, Ignacio Encı́o, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13673-13673
Open Access | Times Cited: 6
Aggressive variant prostate cancer: A case report and literature review
Xiang-Tao Weng, Wen‐Li Lin, Qi-Man Pan, et al.
World Journal of Clinical Cases (2023) Vol. 11, Iss. 26, pp. 6213-6222
Open Access | Times Cited: 6
Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses
Xue Shui, Rong Xu, Caiqin Zhang, et al.
Laboratory Investigation (2021) Vol. 102, Iss. 4, pp. 332-340
Open Access | Times Cited: 13
Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids
Sanghee Lee, Theresa R. Mendoza, Danielle Burner, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3203-3203
Open Access | Times Cited: 10
Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants
Demitria M. Vasilatis, Christopher A. Lucchesi, P. Ghosh
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1100-1100
Open Access | Times Cited: 5
Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer
Stephen Yiu Chuen Choi, Caroline F. Ribeiro, Yuzhuo Wang, et al.
Biomolecules (2022) Vol. 12, Iss. 11, pp. 1590-1590
Open Access | Times Cited: 9
TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer
Yu‐Ching Wen, Yen‐Nien Liu, Hsiu‐Lien Yeh, et al.
Oncogenesis (2021) Vol. 10, Iss. 11
Open Access | Times Cited: 11
Untargeted metabolomics reveals alterations in the metabolic reprogramming of prostate cancer cells by double-stranded DNA-modified gold nanoparticles
Yuting Zhang, Jundong Lin, Yangjia Zhuo, et al.
Biomaterials Advances (2022) Vol. 135, pp. 212745-212745
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top